Cited 0 time in
Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chang, Hyeyoon | - |
| dc.contributor.author | Jung, Woon Yong | - |
| dc.contributor.author | Kang, Youngran | - |
| dc.contributor.author | Lee, Hyunjoo | - |
| dc.contributor.author | Kim, Aeree | - |
| dc.contributor.author | Kim, Baek-hui | - |
| dc.date.accessioned | 2022-07-15T20:41:35Z | - |
| dc.date.available | 2022-07-15T20:41:35Z | - |
| dc.date.issued | 2015-10 | - |
| dc.identifier.issn | 1092-9134 | - |
| dc.identifier.issn | 1532-8198 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156138 | - |
| dc.description.abstract | The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transmembrane protein of receptor tyrosine kinase family. High expression of ROR1 is reported in many types of malignancies and is thought to be involved in tumor growth, apoptosis, and epithelial-mesenchymal transition. In this study, we examined the expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma and analyzed with clinicopathologic factors and tumor proliferation. Tissue microarray blocks containing 424 gastric adenocarcinomas were used for immunohistochemical staining. Ki-67 labeling index was used for tumor proliferation activity. High expression of ROR1 (63%), pAkt (36%), and pCREB (20%) was observed in gastric adenocarcinomas, and expression of these proteins was well intercorrelated. ROR1 and pCREB expression was associated with Ki-67 labeling index (P < .001). Expression of pAkt and pCREB group showed longer survival in univariate analysis (P = .007 and P < .001, respectively). This is the first study that analyzed ROR1 expression in gastric adenocarcinoma tissue samples. We revealed that gastric adenocarcinomas highly express ROR1 and related proteins and its prognostic significance. ROR1 in gastric adenocarcinoma could be possible candidate of therapeutic target and more comprehensive study is required. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | W. B. Saunders Co., Ltd. | - |
| dc.title | Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.anndiagpath.2015.06.010 | - |
| dc.identifier.scopusid | 2-s2.0-84941599335 | - |
| dc.identifier.wosid | 000361642600011 | - |
| dc.identifier.bibliographicCitation | Annals of Diagnostic Pathology, v.19, no.5, pp 330 - 334 | - |
| dc.citation.title | Annals of Diagnostic Pathology | - |
| dc.citation.volume | 19 | - |
| dc.citation.number | 5 | - |
| dc.citation.startPage | 330 | - |
| dc.citation.endPage | 334 | - |
| dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Pathology | - |
| dc.relation.journalWebOfScienceCategory | Pathology | - |
| dc.subject.keywordPlus | RECEPTOR TYROSINE KINASE | - |
| dc.subject.keywordPlus | CHRONIC LYMPHOCYTIC-LEUKEMIA | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordPlus | THERAPY | - |
| dc.subject.keywordPlus | PROTEIN | - |
| dc.subject.keywordPlus | TARGET | - |
| dc.subject.keywordPlus | CREB | - |
| dc.subject.keywordPlus | CELLS | - |
| dc.subject.keywordPlus | HEART | - |
| dc.subject.keywordAuthor | ROR1 | - |
| dc.subject.keywordAuthor | Akt | - |
| dc.subject.keywordAuthor | CREB | - |
| dc.subject.keywordAuthor | Adenocarcinoma | - |
| dc.subject.keywordAuthor | Stomach | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1092913415001148?pes=vor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
